Overview:
Exosomics, founded in 2011 and incubated at the incubator of Fondazione Toscana Life Sciences since 2012, was born as a spin-off of HansaBioMed OU for the exploitation of the EXOTESTTM technology platform, in order to develop multiplexing and validate in this platform a large panel of diagnostic and cancer predictive biomarkers, based on immunometric assays of exosomal biomarkers (proteins and RNA
